{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:13:31Z","timestamp":1770970411217,"version":"3.50.1"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":11,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People with HIV have a greater risk of cardiovascular disease than the general population. Current literature suggests that some ARTs may exacerbate this risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To estimate the risk of hypertension in treatment-na\u00efve people with HIV receiving integrase strand transfer inhibitor (INSTI)\/tenofovir alafenamide (TAF) or INSTI\/non-TAF versus NNRTI\/non-TAF regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Post hoc pooled analysis evaluating data from US participants in five Phase 3 randomized studies. Adjusted prevalence of Stage 1 and 2 hypertension (American College of Cardiology\/American Heart Association criteria) and conditional odds of higher blood pressure ratios were estimated using proportional odds mixed-effect regression through 108\u2005weeks after ART initiation. Time to incident hypertension through 96\u2005weeks was modelled using Cox proportional-hazards regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 2411 participants were included (528, 749 and 1134 received NNRTI\/non-TAF, INSTI\/non-TAF and INSTI\/TAF regimens, respectively). Nearly half of participants had hypertension (Stage \u22651) at baseline. The Week 96 adjusted estimates of risk of hypertension (95% CI) were 1.06 (0.99, 1.13) and 1.12 (0.98, 1.27) for Stages \u22651 and \u22652 hypertension, respectively, for NNRTI\/non-TAF versus INSTI\/non-TAF, and 1.01 (0.95, 1.08) and 1.02 (0.91, 1.17) for Stages \u22651 and \u22652 hypertension, respectively, for NNRTI\/non-TAF versus INSTI\/TAF. There were no significant differences in conditional odds of high blood pressure between treatment groups. No significant differences were identified in time to incident composite hypertension for INSTI\/non-TAF and INSTI\/TAF versus NNRTI\/non-TAF regimens; estimated hazard ratios (approximate 95% CI) were 0.88 (0.66, 1.17) and 0.98 (0.75, 1.28), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results suggest the risk of hypertension is not significantly different across INSTI\/TAF, INSTI\/non-TAF and NNRTI\/non-TAF regimens.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkag005","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:31:55Z","timestamp":1770640315000},"source":"Crossref","is-referenced-by-count":0,"title":["Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3427-6043","authenticated-orcid":false,"given":"Priscilla Y","family":"Hsue","sequence":"first","affiliation":[{"name":"Department of Medicine, University of California, San Francisco , San Francisco, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-1775","authenticated-orcid":false,"given":"Laura","family":"Waters","sequence":"additional","affiliation":[{"name":"Mortimer Market Centre, Central and North West London NHS Foundation Trust , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6168-6745","authenticated-orcid":false,"given":"Chloe","family":"Orkin","sequence":"additional","affiliation":[{"name":"Blizard Institute, Queen Mary University , London ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0073-873X","authenticated-orcid":false,"given":"Juan Manuel","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Bellvitge University Hospital , Barcelona ,","place":["Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3222-9611","authenticated-orcid":false,"given":"Anchalee","family":"Avihingsanon","sequence":"additional","affiliation":[{"name":"HIV-NAT, Thai Red Cross AIDS and Infectious Disease Research Centre , Bangkok ,","place":["Thailand"]},{"name":"Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University , Bangkok ,","place":["Thailand"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Marongiu","sequence":"additional","affiliation":[{"name":"Gilead Sciences Europe Ltd , Uxbridge ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5107-0506","authenticated-orcid":false,"given":"Andrew S","family":"Whiteman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Tian","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2619-7839","authenticated-orcid":false,"given":"Carrie M","family":"Nielson","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2763-8745","authenticated-orcid":false,"given":"Keith","family":"Aizen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calvin","family":"Cohen","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-3423","authenticated-orcid":false,"given":"Jason T","family":"Hindman","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc. , Foster City, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2858-3888","authenticated-orcid":false,"given":"J\u00fcrgen K","family":"Rockstroh","sequence":"additional","affiliation":[{"name":"Department of Medicine, University Hospital Bonn , Bonn ,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"2026021302191567100_dkag005-B1","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","article-title":"The global epidemiology of hypertension","volume":"16","author":"Mills","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026021302191567100_dkag005-B2","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","article-title":"The global burden of cardiovascular diseases and risk: a compass for future health","volume":"80","author":"Vaduganathan","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021302191567100_dkag005-B3","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(21)01330-1","article-title":"Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants","volume":"398","author":"NCD Risk Factor Collaboration","year":"2021","journal-title":"Lancet"},{"key":"2026021302191567100_dkag005-B4","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1161\/CIRCRESAHA.124.323891","article-title":"Inflammation in HIV and its impact on atherosclerotic cardiovascular disease","volume":"134","author":"Obare","year":"2024","journal-title":"Circ Res"},{"key":"2026021302191567100_dkag005-B5","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/CIRCULATIONAHA.117.033369","article-title":"Global burden of atherosclerotic cardiovascular disease in people living with HIV: systematic review and meta-analysis","volume":"138","author":"Shah","year":"2018","journal-title":"Circulation"},{"key":"2026021302191567100_dkag005-B6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1001\/jamacardio.2019.2604","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: part 1, lifestyle and behavioral factors","volume":"4","author":"Arnett","year":"2019","journal-title":"JAMA Cardiol"},{"key":"2026021302191567100_dkag005-B7","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC guidelines for the management of elevated blood pressure and hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"2026021302191567100_dkag005-B8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1513\/pats.201009-058WR","article-title":"Cigarette smoking in the HIV-infected population","volume":"8","author":"Rahmanian","year":"2011","journal-title":"Proc Am Thorac Soc"},{"key":"2026021302191567100_dkag005-B9","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1111\/acer.13204","article-title":"Alcohol use and human immunodeficiency virus (HIV) infection: current knowledge, implications, and future directions","volume":"40","author":"Williams","year":"2016","journal-title":"Alcohol Clin Exp Res"},{"key":"2026021302191567100_dkag005-B10","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/09638288.2016.1260645","article-title":"Global physical activity levels among people living with HIV: a systematic review and meta-analysis","volume":"40","author":"Vancampfort","year":"2018","journal-title":"Disabil Rehabil"},{"key":"2026021302191567100_dkag005-B11","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/jn\/nxy241","article-title":"Diet quality is low and differs by sex in people with HIV","volume":"149","author":"Weiss","year":"2019","journal-title":"J Nutr"},{"key":"2026021302191567100_dkag005-B12","doi-asserted-by":"publisher","first-page":"a007187","DOI":"10.1101\/cshperspect.a007187","article-title":"The HIV-1 epidemic: low- to middle-income countries","volume":"2","author":"Shao","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2026021302191567100_dkag005-B13","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/COH.0000000000000829","article-title":"Clinical consequences of weight gain during treatment for HIV infection","volume":"19","author":"Hill","year":"2024","journal-title":"Curr Opin HIV AIDS"},{"issue":"Suppl. 4","key":"2026021302191567100_dkag005-B14","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/jia2.26279","article-title":"Abacavir is associated with elevated risk for cardiovascular events in the REPRIEVE trial","volume":"27","author":"Fichtenbaum","year":"2024","journal-title":"J Int AIDS Soc"},{"key":"2026021302191567100_dkag005-B15","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1111\/hiv.13273","article-title":"Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium","volume":"23","author":"Byonanebye","year":"2022","journal-title":"HIV Med"},{"key":"2026021302191567100_dkag005-B16","doi-asserted-by":"publisher","first-page":"ofz491","DOI":"10.1093\/ofid\/ofz491","article-title":"Short-term increase in risk of overweight and concomitant systolic blood pressure elevation in treatment-naive persons starting INSTI-based antiretroviral therapy","volume":"6","author":"Galdamez","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026021302191567100_dkag005-B17","doi-asserted-by":"publisher","first-page":"101836","DOI":"10.1016\/j.eclinm.2023.101836","article-title":"Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South Africa","volume":"57","author":"Brennan","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026021302191567100_dkag005-B18"},{"key":"2026021302191567100_dkag005-B19","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet"},{"key":"2026021302191567100_dkag005-B20","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"2026021302191567100_dkag005-B21","doi-asserted-by":"publisher","first-page":"e389","DOI":"10.1016\/S2352-3018(20)30099-0","article-title":"Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials","volume":"7","author":"Orkin","year":"2020","journal-title":"Lancet HIV"},{"key":"2026021302191567100_dkag005-B22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1097\/QAD.0000000000003865","article-title":"Switch to bictegravir\/emtricitabine\/tenofovir alafenamide from dolutegravir-based therapy","volume":"38","author":"Orkin","year":"2024","journal-title":"AIDS"},{"key":"2026021302191567100_dkag005-B23","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","article-title":"Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials","volume":"59","author":"Sax","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026021302191567100_dkag005-B24","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"2026021302191567100_dkag005-B25","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","article-title":"Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"2026021302191567100_dkag005-B26","doi-asserted-by":"publisher","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","article-title":"Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"2026021302191567100_dkag005-B27","author":"Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure"},{"key":"2026021302191567100_dkag005-B28","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1097\/EDE.0000000000001380","article-title":"Multiple-bias sensitivity analysis using bounds","volume":"32","author":"Smith","year":"2021","journal-title":"Epidemiology"},{"key":"2026021302191567100_dkag005-B29","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.jacc.2007.08.017","article-title":"A prospective study of cigarette smoking and risk of incident hypertension in women","volume":"50","author":"Bowman","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2026021302191567100_dkag005-B30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1620\/tjem.217.37","article-title":"Smoking as an independent risk factor for hypertension: a 14-year longitudinal study in male Japanese workers","volume":"217","author":"Dochi","year":"2009","journal-title":"Tohoku J Exp Med"},{"key":"2026021302191567100_dkag005-B31","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/ajh.2007.36","article-title":"Smoking and the risk of incident hypertension in middle-aged and older men","volume":"21","author":"Halperin","year":"2008","journal-title":"Am J Hypertens"},{"key":"2026021302191567100_dkag005-B32","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/01621459.1977.10480613","article-title":"The efficiency of Cox\u2019s likelihood function for censored data","volume":"72","author":"Efron","year":"1977","journal-title":"J Am Stat Assoc"},{"key":"2026021302191567100_dkag005-B33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1161\/HYPERTENSIONAHA.118.10893","article-title":"Hypertension in HIV-infected adults: novel pathophysiologic mechanisms","volume":"72","author":"Fahme","year":"2018","journal-title":"Hypertension"},{"key":"2026021302191567100_dkag005-B34","first-page":"1","article-title":"Hypertension prevalence among adults aged 18 and over: United States, 2017\u20132018","volume":"364","author":"Ostchega","year":"2020","journal-title":"NCHS Data Brief"},{"key":"2026021302191567100_dkag005-B35","first-page":"1","article-title":"Hypertension prevalence, awareness, treatment, and control among adults age 18 and older: United States, August 2021\u2013August 2023","volume":"511","author":"Fryar","year":"2024","journal-title":"NCHS Data Brief"},{"key":"2026021302191567100_dkag005-B36","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/cid\/ciu869","article-title":"Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults","volume":"60","author":"Althoff","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B37","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1093\/gerona\/glt168","article-title":"Is HIV a model of accelerated or accentuated aging?","volume":"69","author":"Pathai","year":"2014","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026021302191567100_dkag005-B38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.hjc.2022.12.013","article-title":"Cardiovascular disease and risk assessment in people living with HIV: current practices and novel perspectives","volume":"71","author":"Fragkou","year":"2023","journal-title":"Hellenic J Cardiol"},{"key":"2026021302191567100_dkag005-B39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12916-014-0125-2","article-title":"Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study","volume":"12","author":"Peck","year":"2014","journal-title":"BMC Med"},{"key":"2026021302191567100_dkag005-B40","doi-asserted-by":"publisher","first-page":"e013744","DOI":"10.1161\/JAHA.119.013744","article-title":"Excess risk for atherosclerotic cardiovascular outcomes among US adults with HIV in the current era","volume":"9","author":"Rosenson","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026021302191567100_dkag005-B41","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1161\/CIR.0000000000000677","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"2026021302191567100_dkag005-B42","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2304146","article-title":"Pitavastatin to prevent cardiovascular disease in HIV infection","volume":"389","author":"Grinspoon","year":"2023","journal-title":"N Engl J Med"},{"key":"2026021302191567100_dkag005-B43","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1056\/NEJMoa062360","article-title":"CD4+ count-guided interruption of antiretroviral treatment","volume":"355","author":"El-Sadr","year":"2006","journal-title":"N Engl J Med"},{"key":"2026021302191567100_dkag005-B44","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1086\/654817","article-title":"Circulating Nef induces dyslipidemia in simian immunodeficiency virus-infected macaques by suppressing cholesterol efflux","volume":"202","author":"Asztalos","year":"2010","journal-title":"J Infect Dis"},{"key":"2026021302191567100_dkag005-B45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1093\/cid\/ciad286","article-title":"Impact of integrase inhibitors on cardiovascular disease events in people with human immunodeficiency virus starting antiretroviral therapy","volume":"77","author":"Surial","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B46","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dky145","article-title":"Obesity following ART initiation is common and influenced by both traditional and HIV-\/ART-specific risk factors","volume":"73","author":"Bakal","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2026021302191567100_dkag005-B47","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B48","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B49","doi-asserted-by":"publisher","first-page":"e2332968","DOI":"10.1001\/jamanetworkopen.2023.32968","article-title":"Use of tenofovir alafenamide fumarate for HIV pre-exposure prophylaxis and incidence of hypertension and initiation of statins","volume":"6","author":"Rivera","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026021302191567100_dkag005-B50","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/cid\/ciae191","article-title":"Antiretrovirals and weight change: weighing the evidence","volume":"79","author":"Wohl","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B51","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1093\/jac\/dkae238","article-title":"Low CD4 counts predict excessive weight gains during first-line treatment for HIV","volume":"79","author":"Hill","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2026021302191567100_dkag005-B52","doi-asserted-by":"publisher","first-page":"e3902","DOI":"10.1093\/cid\/ciaa1073","article-title":"CYP2B6 genotype and weight gain differences between dolutegravir and efavirenz","volume":"73","author":"Griesel","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026021302191567100_dkag005-B53","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jacc.2018.10.069","article-title":"Blood pressure assessment in adults in clinical practice and clinic-based research: JACC scientific expert panel","volume":"73","author":"Muntner","year":"2019","journal-title":"J Am Coll Cardiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag005\/66887772\/dkag005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag005\/66887772\/dkag005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:19:22Z","timestamp":1770967162000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag005\/8482229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag005","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag005"}}